Chugai's picibanil (OK-432)
Executive Summary
Immune stimulant is currently undergoing Phase I/II study at the Pittsburgh Cancer Institute (PCI) in a two-year cancer study involving 80 patients. Picibanil is the third most widely-used anticancer drug in Japan, PCI reports.